Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Stanford Medicine

Sites in Stanford & Palo Alto, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 2:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1366
Shown on this page
12
Current sort
Recently updated
Campus scope
Stanford Medicine, Stanford & Palo Alto, CA
Additional filters apply within this campus.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this campus

These controls apply only within Stanford Medicine, Stanford & Palo Alto, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 793–804 of 1,366 matching trials with a site at Stanford Medicine, Stanford & Palo Alto, CA.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Active, not recruiting Phase 2 Interventional Results available

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

NCT04195555
Site status not listed — check the official record
View directory record Official record
Conditions
Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
Interventions
Ivosidenib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
171
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 16, 2026, 2:44 PM EDT
Recruiting Phase 1 Interventional

TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation

NCT03943238
Status at this site: Recruiting
View directory record Official record
Conditions
Living Donor Kidney Transplantation
Interventions
Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 29, 2026, 5:38 AM EDT
Recruiting Phase 1 Interventional

Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs.

NCT03591302
Status at this site: Recruiting
View directory record Official record
Conditions
Immune Tolerance
Interventions
Hematopoietic cell transplantation, Total Lymphoid irradiation
Biological · Radiation
Lead sponsor
Stephan Busque
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 29, 2026, 5:24 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Magnetic Resonance Imaging of Breast Cancer

NCT01035112
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Non-invasive Breast Cancer
Interventions
MRI
Procedure
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Aug 1, 2026, 10:31 PM EDT
Recruiting No phase listed Observational

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

NCT00568490
Status at this site: Recruiting
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Cancers, Lip Cancer, Lip Neoplasms, Lung Cancer
Interventions
Phlebotomy, Tumor biopsy
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 26, 2026, 10:43 PM EDT
Recruiting No phase listed Observational

Follow-up Visit of High Risk Infants

NCT00009633
Status at this site: Recruiting
View directory record Official record
Conditions
Infant, Low Birth Weight, Infant, Newborn, Infant, Premature, Infant, Small for Gestational Age
Interventions
No Intervention
Other
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
18 Months to 26 Months
Enrollment
68,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2030
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 27, 2026, 11:36 PM EDT
Not yet recruiting Not applicable Interventional

A Pilot Study Using Gut-Directed Hypnotherapy for Hospitalized Patients

NCT07676136
Site status not listed — check the official record
View directory record Official record
Conditions
Abdominal Pain, Disorders of Gut-brain Interaction, Esophageal Disease, Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome
Interventions
Educational recording, Gut directed hypnotherapy via telephone intervention
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Aug 1, 2026, 11:21 PM EDT
Not yet recruiting Not applicable Interventional

Personalized Blood Transfusion Protocol for Cardiac Patients

NCT07671469
Site status not listed — check the official record
View directory record Official record
Conditions
Anemia, Blood Transfusion, Cardiac Surgery, Cardiopulmonary Bypass
Interventions
Demand-Informed Transfusion Decision Rule
Other
Lead sponsor
Yan Mia Min
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Aug 13, 2026, 3:56 AM EDT
Active, not recruiting Phase 2 Interventional

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

NCT06449222
Site status not listed — check the official record
View directory record Official record
Conditions
Locally Advanced Breast Cancer, Metastatic Triple Negative Breast Cancers, Triple Negative Breast Cancer
Interventions
BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), BNT327 Equivalent Q3W Dose, BNT327 Optimized Dose, Carboplatin, Eribulin, Gemcitabine, Nab-placlitaxel, Paclitaxel
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 3, 2026, 8:05 PM EDT
Recruiting Phase 1 Interventional

Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

NCT06201416
Status at this site: Recruiting
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SBT777101
Biological
Lead sponsor
Sonoma Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • San Francisco, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 14, 2026, 10:06 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Blossom® Smart Expander Device for Tissue Expander/Implant-Based Breast Reconstruction

NCT05975372
Status at this site: Recruiting
View directory record Official record
Conditions
Implant Based Breast Reconstruction, Tissue Expansion
Interventions
Blossom tissue expander, Standard tissue expansion
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Aug 21, 2026, 10:03 PM EDT
Active, not recruiting Not applicable Interventional

Telehealth Treatment for Alcohol Use Disorder

NCT05747703
Site status not listed — check the official record
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Use Disorder, Alcoholism
Interventions
Ria Treatment Platform
Combination Product
Lead sponsor
Ria Health
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Aug 2, 2026, 4:34 AM EDT

About this Stanford Medicine institution page

What this page lists
ClinicalTrials.gov records that list Stanford Medicine in Stanford & Palo Alto, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Stanford University at any site, browse by condition, or browse by U.S. city.